By Ben Glickman
Neurocrine Biosciences and Lupin resolved patent litigation related to Neurocrine’s Ingrezza medication.
Lupin will have the right to sell generic versions of the treatment of tardive dyskinesia and chorea associated with Huntington’s disease starting March 1, 2038.
Neurocrine still faces similar patent litigation seeking to market generic Ingreza, and the company has already reached similar agreements with Sandoz and Teva Pharmaceuticals.
Lupin may be able to sell the generic Ingrezza earlier than the 2038 date under certain circumstances.
Write to Ben Glickman at [email protected]
Read the full article here
